Loading...
•
Jun 30, 2021
Black Diamond Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported its Q2 2021 financial results, highlighting the advancement of its clinical and pre-clinical pipeline, including BDTX-189, BDTX-1535, BRAF, and FGFR programs. The company's cash, cash equivalents, and investments totaled $263.5 million as of June 30, 2021.
Presented initial Phase 1 clinical data for BDTX-189 at ASCO Annual Meeting and is on track to initiate Phase 2 portion of MasterKey-01 study in the second half of 2021.
Presented pre-clinical data for BDTX-1535 at AACR Annual Meeting and is on track to enter the clinic in 2022.
Early-stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022.
Appointed Mark Velleca, M.D., Ph.D., to Board of Directors.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...